

NYU Lutheran Family Health Center (NYU-LFHC), the FQHC outpatient component of the NYU Lutheran Psychiatry Service, is actively recruiting for multiple openings within our Behavioral Health Service Line. NYU-LFHC offers evidence based individualized treatment services for individuals managing mental health disorders, struggling with chemical dependency problems and/or coping with health issues associated with HIV/AIDS. Services are provided by multidisciplinary, multilingual, culturally competent treatment teams composed of physicians, nurses, psychologists, social workers and addiction counselors.


Recruitment is ongoing for the following openings:

1. Network Behavioral Health Medical Director. Strong background/ interest in community mental health, provides overall psychiatric leadership for all ambulatory behavioral health services. Including supervision and direction of the delivery of clinical services by all licensed and credentialed behavioral health providers, any health professions students and trainees assigned.
2. Child and Adolescent Psychiatrist: Will serve as Associate Medical Director and be responsible for evaluation of patients, diagnosis of illness, overall treatment planning, implementation and follow-up of treatment, and disposition of psychiatric patients. Participates in development of clinical programs and supervision of clinical staff participating in such programs.
3. Adult Psychiatrists (3 positions): Responsible for evaluation of patients, diagnosis of illness, overall treatment planning, implementation and follow-up of treatment, and disposition of psychiatric patients, in the outpatient setting. Specialization in addiction treatment is preferred for one of the open positions.

Learn more about our program and apply for a position by sending your CV to: **W. Gordon Frankle, MD, MBA, Chief, NYU Lutheran Psychiatry Service, and Sean Pavlow, Administrative Director, NYU Lutheran Psychiatry Service at Sean.Pavlow@nyumc.org**

Pocket Guide to Addiction Assessment and Treatment

Edited by Petros Levounis, M.D., M.A.,
Erin Zerbo, M.D., and Rashi Aggarwal, M.D.



The *Pocket Guide to Addiction Assessment and Treatment* is designed specifically to aid a wide range of clinicians, regardless of their training in addiction, to more confidently assess and treat this patient population. With an accessible, easily referenced format, this book serves as a go-to resource for general psychiatrists other practitioners involved in the addiction treatment field. And because all of the diagnostic discussions are DSM-5⁺-based, readers can be confident that they're getting the most relevant and up-to-date guidance on the topic.

2016 • 379 pages • ISBN 978-1-58562-512-3 • Paperback \$65.00 • Item #62512

2016 • 379 pages • ISBN 978-1-58562-512-3 • eBook \$52.00 • Item #37072

PS Form 3526 Statement of Ownership, Management, and Circulation (All Periodicals Publications Except Requester Publications)

1. Publication Title AMERICAN PSYCHIATRIC ASSOCIATION/ AMERICAN JOURNAL OF PSYCHIATRY (THE)	2. Publication Number 20200	ISSN 29530	3. Filing Date 09/29/2016
4. Issue Frequency MONTHLY	5. Number of Issues Published Annually 12	6. Annual Subscription Price \$ 306.00	
7. Complete Mailing Address of Known Office of Publication 1000 WILSON BLVD STE 1825 ARLINGTON, VA 22209-3924			Contact Person ROGER DOMRAS Telephone (703) 907-8544
8. Complete Mailing Address of Headquarters or General Business Office of Publisher 1000 Wilson Blvd., Ste. 1825 Arlington, VA 22209-3924			
9. Full Names and Complete Mailing Addresses of Publisher, Editor, and Managing Editor			
Publisher (Name and complete mailing address) Rebecca Rinehart 1000 Wilson Blvd., Ste. 1825 Arlington, VA 22209-3924			
Editor (Name and complete mailing address) Robert Freedman, M.D. 1000 Wilson Blvd., Ste. 1825 Arlington, VA 22209-3924			
Managing Editor (Name and complete mailing address) Michael Roy 1000 Wilson Blvd., Ste. 1825 Arlington, VA 22209-3924			
10. Owner (Do not leave blank. If the publication is owned by a corporation, give the name and address of the corporation immediately followed by the names and addresses of all stockholders owning or holding 1 percent or more of the total amount of stock. If not owned by a corporation, give names and addresses of the individual owners. If owned by a partnership or other unincorporated firm, give its name and address as well as those of each individual owner. If the publication is published by a nonprofit organization, give its name and address.)			
Full Name American Psychiatric Assoc.	Complete Mailing Address 1000 Wilson Blvd., Ste. 1825, Arlington, VA 22209-3924		
11. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages, or Other Securities. If none, check box <input checked="" type="checkbox"/> None			
Full Name	Complete Mailing Address		
PS Form 3526, September 2007 (Page 1) PRIVACY NOTICE: See our privacy policy on www.usps.com			

13. Publication Title AMERICAN PSYCHIATRIC ASSOCIATION/AMERICAN JOURNAL OF PSYCHIATRY (THE)	14. Issue Date for Circulation Data Below 09/01/2016	
15. Extend and Nature of Circulation	Average No. Copies Each Issue During Preceding 12 Months	No. Copies of Single Issue Published Nearest to Filing Date
a. Total Numbers of Copies (Net press run)	29861	29614
b. Paid Circulation (By Mail and Outside the Mail)		
(1) Mailed Outside County Paid Subscriptions Stated on PS Form 3541 (include paid distribution above nominal rate, advertiser's proof copies, and exchange copies)	26225	26263
(2) Mailed In-County Paid Subscriptions Stated on PS Form 3541 (include paid distribution above nominal rate, advertiser's proof copies, and exchange copies)	0	0
(3) Paid Distribution Outside the Mails Including Sales Through Dealers and Carriers, Street Vendors, Counter Sales, and Other Paid Distribution Outside USPS	2251	2497
(4) Paid Distribution by Other Classes of Mail Through the USPS (e.g. First-Class Mail)	0	0
c. Total Paid Distribution (Sum of 15b (1), (2), (3), (4))	28476	28760
d. Free or Nominal Rate Distribution (By Mail and Outside the Mail)		
(1) Free or Nominal Rate Outside County Copies included on PS Form 3541	371	376
(2) Free or Nominal Rate In-County Copies included on PS Form 3541	0	0
(3) Free or Nominal Rate Copies Mailed at Other Classes Through the USPS (e.g. First-Class Mail)	0	0
(4) Free or Nominal Rate Distribution Outside the Mail (Carriers or other means)	106	94
e. Total Free or Nominal Rate Distribution (Sum of 15d (1), (2), (3), (4))	477	470
f. Total Distribution (Sum of 15c and 15e)	28953	29230
g. Copies not Distributed	0	0
h. Total (Sum of 15f and 15g)	28953	29230
i. Percent Paid (15c / 15f times 100)	98.35 %	98.39 %
16. If total circulation includes electronic copies, report that circulation on lines below.		
a. Paid Electronic Copies	0	0
b. Total Paid Print Copies (Line 15c) + Paid Electronic Copies	0	0
c. Total Print Distribution (Line 15f) + Paid Electronic Copies	0	0
d. Percent Paid (Both Print and Electronic Copies)	0.00 %	0.00 %
<input type="checkbox"/> I certify that 50% of all my distributed copies (Electronic and Print) are paid above a nominal price.		
17. Publication of Statement of Ownership <input checked="" type="checkbox"/> If the publication is a general publication, publication of this statement is required. Will be printed in the 11/01/2016 issue of this publication. <input type="checkbox"/> Publication not required.		
18. Signature and Title of Editor, Publisher, Business Manager, or Owner Peter Van Worden	Title Dir. Finance Publishing Operations	Date 09/29/2016 00:00:00 AM
I certify that all information furnished on this form is true and complete. I understand that anyone who furnishes false or misleading information on this form or who omits material or information requested on the form may be subject to criminal sanctions (including fines and imprisonment) and/or civil sanctions (including civil penalties).		
PS Form 3526, September 2007 (Page 2) PRIVACY NOTICE: See our privacy policy on www.usps.com		

University of California
San Francisco



School of Medicine
Fresno Medical Education Program



UCSF FRESNO PSYCHIATRY FACULTY OPPORTUNITY

The University of California San Francisco Fresno Medical Education Program (UCSF Fresno) and Central California Faculty Medical Group (CCFMG) are seeking candidates for a 1.0 FTE faculty member for the Fresno County Mental Health in Fresno. The physician (Psychiatrist) will work primarily in an outpatient program. Fresno County Mental Health is a core training site for UCSF Fresno Residency training program in numerous specialties and Fellowships including Psychiatry. With a faculty appointment, opportunities for resident supervision, teaching and clinical research will be available and encouraged. Board certification in Adult Psychiatry is required. California licensed or eligibility to obtain a California license is required.

The program is based in Fresno, California, where residents enjoy a high standard of living combined with a low cost of living. The result is a quality of life uniquely Californian, yet surprisingly affordable. Limitless recreational opportunities and spectacular scenery is all accessible in a community with abundant affordable housing. While there is much to see and do in Fresno, the city is ideally located for fast, convenient getaways to the majestic Sierra (just 90 minutes away) as well as the scenic Central Coast, just two and one-half hours away. Fresno is the only major city in the country with close proximity to three national parks, including renowned Yosemite National Park.

PLEASE APPLY ONLINE AT: <https://aprecruit.ucsf.edu/apply/JPF01054>

Visit our websites:

www.universitymds.com www.fresno.ucsf.edu www.communitymedical.org

UC San Francisco seeks candidates whose experience, teaching, research, or community service that has prepared them to contribute to our commitment to diversity and excellence.

The University of California is an Equal Opportunity/Affirmative Action Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, age or protected veteran status.

Adult Psychiatrist Opportunities

Positions in Missouri

SIGN ON BONUS & RESIDENCY STIPEND AVAILABLE

Mercy Clinic, a regional and national recognized leader in healthcare, is seeking BE/BC Adult Psychiatrists to join our teams in Missouri on the campus of Mercy Hospital Jefferson and at our McAuley Clinic at Mercy Hospital Washington.

This Position Offers:

- Integrated health system with a competitive income guarantee.
- Comprehensive benefits including health, dental, vision and CME.
- Relocation assistance and professional liability coverage.
- System-wide EPIC EMR.
- Sponsorship of H1B Visa.

Opportunities:

Mercy McAuley Clinic provides prenatal and pediatric care to uninsured, underinsured and Medicaid-eligible women and children in more than five counties. Primary responsibilities will be to provide outpatient services four-days a week at our clinic. No call or weekend responsibilities.

Mercy Hospital Jefferson has a contracted team that provides Inpatient coverage in our 60 bed unit (both Adult & Geriatrics) & 12 bed medical/psychiatric units. Primary responsibilities will be both outpatient practice and IOP program.

For more information, please contact:

Lisa Hauck, MBA
Senior Physician Recruiter
314-364-3840 | Fax: 314-364-2597
lisa.hauck@mercy.net | www.mercy.net



PHYSICIAN OPPORTUNITIES GENERAL PSYCHIATRY POSITIONS

Fayetteville is a progressive city with diverse population located in SE NC, close to Fort Bragg. It has superb parks, lakes, cultural activities, restaurants, sporting events, concerts, museums, and excellent schools. The Medical Center is a 126-bed hospital with inpatient services in Medical/surgery/telemetry, mental health, ICU, long-term care, Urgent Care Center (UCC). The new Health Care Center located on South Raeford Road provides primary care and most medical/surgical subspecialties.

Requirements: US Citizen. Current, full unrestricted medical license, certification, or registration required in any state, Territory, Commonwealth, or DC. Proficient in spoken and written English. Pass a pre-employment medical exam. Pass a background security investigation. Selective Service Registration is required for males born after 12/31/1959.

Preferred Experience: Degree in medicine or an equivalent degree from an accredited school. Completed a residency in Psychiatry from an accredited program. Has academic experience teaching to assist with developing functions of the MHSL in the training of residents and interns and the development of scholarly activities.

Exceptional Benefits: Health and life insurance, retirement, Thrift Savings Plan (TSP), generous leave, malpractice insurance, recruitment/Relocation incentive and Education Debt Reduction Program. Yearly Pay for Performance incentive up to \$15K. Salary is commensurate with experience and qualifications.

Interested candidates should submit a cover letter and curriculum vitae along with three references.

Clayton Blake, Physician Recruiter
Human Resources Management Service (05)
VA Medical Center, 2300 Ramsey Street, Fayetteville, NC 28301
Phone: 910-488-2120, x5439, Email: clayton.blake@va.gov,
or Fax: 910-822-7129

Full-Time Employment | Equal Opportunity Employer

Subscription and Business Information

The American Journal of Psychiatry, ISSN 0002-953X, is published monthly by the American Psychiatric Association.

The American Psychiatric Association does not hold itself responsible for statements made in its publications by contributors or advertisers. Unless so stated, material in *The American Journal of Psychiatry* does not reflect the endorsement, official attitude, or position of the American Psychiatric Association or of the Journal's Editorial Board.

Periodicals postage paid at Arlington, VA, and additional mailing offices. POSTMASTER: Send address changes to *The American Journal of Psychiatry*, Circulation Department, American Psychiatric Association, 1000 Wilson Blvd., Suite 1825, Arlington, VA 22209-3901.

Editorial Office

American Journal of Psychiatry
American Psychiatric Association
1000 Wilson Blvd., Suite 1825
Arlington, VA 22209-3901
Phone: (703) 907-7885, (703) 907-7889
E-mail: ajp@psych.org

Customer Service

Phone: (800) 368-5777 (toll-free)
E-mail: appi@psych.org

APA Member Subscription Services

Phone: (888) 35-PSYCH (toll-free)

Subscriptions

Per year: individual \$294.00,
international \$442.00

Institutional subscriptions are tier priced. For institutional site license or pricing information, contact (703) 907-8538 or institutions@psych.org.

Additional subscription options, including single issues and student rates

Contact Customer Service

Advertising

Pharmaceutical Print and Online Advertising
Frank Cox, Kathleen Harrison, Tim Wolfinger
Pharmaceutical Media, Inc.
30 East 33rd Street
New York, NY 10016
Phone: (212) 904-0379
E-mail: twolfinger@pminy.com

Nonpharmaceutical and Online Sales

Eamon Wood
Pharmaceutical Media, Inc.
E-mail: ewood@pminy.com
(see address and phone above).

Permissions and Reprints

Material published in the journals of the American Psychiatric Association and American Psychiatric Association Publishing is protected by copyright and all rights are reserved. Material may not be reproduced in any form or by any means without written permission from the copyright owner. For permission to reproduce material published by APA, please visit http://www.appi.org/Customer_Service/Pages/Permissions.aspx for more information. Permission can also be secured through the Copyright Clearance Center (www.copyright.com).

APA does not require that permission be obtained for the photocopying of isolated articles for nonprofit classroom or library reserve use; all fees associated with such permission are waived. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Requests for commercial distribution should be directed to (703) 907-7875.

For bulk reprints, please contact Jane Cha, (703) 907-7889; email: jcha@psych.org.

Indexed in Abstracts for Social Workers, Academic Abstracts, Biological Abstracts, Chemical Abstracts, Chicago Psychoanalytic Literature Index, Cumulative Index to Nursing Literature, Excerpta Medica, Hospital Literature Index, Index Medicus, International Nursing Index, Nutrition Abstracts, Psychological Abstracts, Science Citation Index, Social Science Source, and Social Sciences Index.

Pages are produced by Dartmouth Journal Services, Waterbury, VT, and printed by Dartmouth Printing Company, Hanover, NH, on acid-free paper effective with Volume 169, Number 1, January 2012.

© 2016 American Psychiatric Association.



BRIEF SUMMARY OF FULL PRESCRIBING INFORMATION. See package insert for full Prescribing Information. For further product information and current package insert, please visit www.pristiqhcp.com or call Pfizer US Medical Information toll-free at (800) 438-1985.

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see Warnings and Precautions (5.1) in the full prescribing information]. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see Warnings and Precautions (5.1) in the full prescribing information]. PRISTIQ is not approved for use in pediatric patients [see Use in Specific Populations (8.4) in the full prescribing information].

INDICATIONS AND USAGE: PRISTIQ, a serotonin and norepinephrine reuptake inhibitor (SNRI), is indicated for the treatment of major depressive disorder (MDD) [see Clinical Studies (14) and Dosage and Administration (2.1) in the full prescribing information]. The efficacy of PRISTIQ has been established in four short-term (8-week, placebo-controlled studies) and two maintenance studies in adult outpatients who met DSM-IV criteria for major depressive disorder.

CONTRAINDICATIONS: Hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or to any excipients in the PRISTIQ formulation. Angioedema has been reported in patients treated with PRISTIQ [see Adverse Reactions (6.1) in the full prescribing information]. The use of monoamine oxidase inhibitors (MAOIs) intended to treat psychiatric disorders with PRISTIQ or within 7 days of stopping treatment with PRISTIQ is contraindicated because of an increased risk of serotonin syndrome. The use of PRISTIQ within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated [see Dosage and Administration (2.6) and Warnings and Precautions (5.2) in the full prescribing information]. Starting PRISTIQ in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see Dosage and Administration (2.6) and Warnings and Precautions (5.2) in the full prescribing information].

WARNINGS AND PRECAUTIONS: Suicidal Thoughts and Behaviors in Children, Adolescents and Young Adults—Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled studies of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with major depressive disorder (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older. The pooled analyses of placebo-controlled studies in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term studies of 9 antidepressant drugs in over 4,400 patients. The pooled analyses of placebo-controlled studies in adults with MDD or other psychiatric disorders included a total of 295 short-term studies (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs. placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1,000 patients treated) included 14 additional cases of increases among those aged <18, 5 additional cases of increases among those aged 18 to 24, 1 fewer case of decrease among those aged 25 to 64, and 6 fewer cases of decrease among those aged ≥65.

No suicides occurred in any of the pediatric studies. There were suicides in the adult studies, but the number was not sufficient to reach any conclusion about drug effect on suicide. It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance studies in adults with depression that the use of antidepressants can delay the recurrence of depression. All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality. Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms. If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms [see Dosage and Administration (2.4) and Warnings and Precautions (5.7) in the full prescribing information for a description of the risks of discontinuation of PRISTIQ]. Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to healthcare providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for PRISTIQ should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose. **Screening patients for bipolar disorder—**A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled studies) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It should be noted that PRISTIQ is not approved for use in treating bipolar depression. **Serotonin Syndrome:** The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including PRISTIQ, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fenfluramine, lithium, tramadol, tryptophan, buspirone, and St. John's Wort), and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue). Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome. The concomitant use of PRISTIQ with MAOIs intended to treat psychiatric disorders is contraindicated. PRISTIQ should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information

on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses. There may be circumstances when it is necessary to initiate treatment with a MAOI such as linezolid or intravenous methylene blue in a patient taking PRISTIQ. PRISTIQ should be discontinued before initiating treatment with the MAOI [see Contraindications (4.2) and Dosage and Administration (2.6) in the full prescribing information]. If concomitant use of PRISTIQ with other serotonergic drugs, including triptans, tricyclic antidepressants, fenfluramine, tramadol, buspirone, tryptophan, and St. John's Wort is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. Treatment with PRISTIQ and any concomitant serotonergic agents should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated. **Elevated Blood Pressure:** Patients receiving PRISTIQ should have regular monitoring of blood pressure since increases in blood pressure were observed in clinical studies [see Adverse Reactions (6.1) in the full prescribing information]. Pre-existing hypertension should be controlled before initiating treatment with PRISTIQ. Caution should be exercised in treating patients with pre-existing hypertension, cardiovascular, or cerebrovascular conditions that might be compromised by increases in blood pressure. Cases of elevated blood pressure requiring immediate treatment have been reported with PRISTIQ. Sustained blood pressure increases could have adverse consequences. For patients who experience a sustained increase in blood pressure while receiving PRISTIQ, either dose reduction or discontinuation should be considered [see Adverse Reactions (6.1) in the full prescribing information]. **Abnormal Bleeding:** SSRIs and SNRIs, including PRISTIQ, may increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anticoagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Bleeding events related to SSRIs and SNRIs have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages. Patients should be cautioned about the risk of bleeding associated with the concomitant use of PRISTIQ and NSAIDs, aspirin, or other drugs that affect coagulation or bleeding. **Angle Closure Glaucoma:** The pupillary dilation that occurs following the use of many antidiuretic drugs including PRISTIQ may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy. **Activation of Mania/Hypomania:** During all MDD phase 2 and phase 3 studies, mania was reported for approximately 0.02% of patients treated with PRISTIQ. Activation of mania/hypomania has also been reported in a small proportion of patients with major affective disorder who were treated with other marketed antidepressants. As with all antidepressants, PRISTIQ should be used cautiously in patients with a history or family history of mania or hypomania. **Discontinuation Syndrome:** Discontinuation symptoms have been systematically and prospectively evaluated in patients treated with PRISTIQ during clinical studies in Major Depressive Disorder. Abrupt discontinuation or dose reduction has been associated with the appearance of new symptoms that include dizziness, nausea, headache, irritability, insomnia, diarrhea, anxiety, fatigue, abnormal dreams, and hyperhidrosis. In general, discontinuation events occurred more frequently with longer duration of therapy. During marketing of SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors), and SSRIs (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesia, such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms. Patients should be monitored for these symptoms when discontinuing treatment with PRISTIQ. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate [see Dosage and Administration (2.4) and Adverse Reactions (6.1) in the full prescribing information]. **Seizure:** Cases of seizure have been reported in pre-marketing clinical studies with PRISTIQ. PRISTIQ has not been systematically evaluated in patients with a seizure disorder. Patients with a history of seizures were excluded from pre-marketing clinical studies. PRISTIQ should be prescribed with caution in patients with a seizure disorder. **Hypotension:** Hypotension may occur as a result of treatment with SSRIs and SNRIs, including PRISTIQ. In many cases, this hypotension appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Cases with serum sodium lower than 110 mmol/L have been reported. Elderly patients may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk [see Use in Specific Populations (8.5) and Clinical Pharmacology (12.6) in the full prescribing information]. Discontinuation of PRISTIQ should be considered in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted. Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls. Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death. **Interstitial Lung Disease and Eosinophilic Pneumonia:** Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine (the parent drug of PRISTIQ) therapy have been rarely reported. The possibility of these adverse events should be considered in patients treated with PRISTIQ who present with progressive dyspnea, cough, or chest discomfort. Such patients should undergo a prompt medical evaluation, and discontinuation of PRISTIQ should be considered.

ADVERSE REACTIONS: The following adverse reactions are discussed in greater detail in other sections of the label: Hypersensitivity [see Contraindications (4)], Suicidal Thoughts and Behaviors in Adolescents and Young Adults [see Warnings and Precautions (5.1)], Serotonin Syndrome [see Warnings and Precautions (5.2)], Elevated Blood Pressure [see Warnings and Precautions (5.3)], Abnormal Bleeding [see Warnings and Precautions (5.4)], Angle Closure Glaucoma [see Warnings and Precautions (5.5)], Activation of Mania/Hypomania [see Warnings and Precautions (5.6)], Discontinuation Syndrome [see Warnings and Precautions (5.7)], Seizure [see Warnings and Precautions (5.8)], Hypotension [see Warnings and Precautions (5.9)], Interstitial Lung Disease and Eosinophilic Pneumonia [see Warnings and Precautions (5.10)]. **Clinical Studies Experience:** Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice. **Patient exposure—**PRISTIQ was evaluated for safety in 8,394 patients diagnosed with major depressive disorder who participated in multiple-dose pre-marketing studies, representing 2,784 patient-years of exposure. Of the total 8,394 patients exposed to at least one dose of PRISTIQ, 2,116 were exposed to PRISTIQ for 6 months, representing 1,658 patient-years of exposure, and 421 were exposed for one year, representing 416 patient-years of exposure. **Adverse reactions reported as reasons for discontinuation of treatment—**In the pre-marketing pooled 8-week placebo-controlled studies in patients with MDD, 1,834 patients were exposed to PRISTIQ (50 to 400 mg). Of the 1,834 patients, 12% discontinued treatment due to an adverse reaction, compared with 3% of the 1,116 placebo-treated patients. At the recommended dose of 50 mg, the discontinuation rate due to an adverse reaction for PRISTIQ (4.1%) was similar to the rate for placebo (3.8%). For the 100 mg dose of PRISTIQ the discontinuation rate due to an adverse reaction was 8.7%. The most common adverse reactions leading to discontinuation in at least 2% and at a rate greater than placebo of the PRISTIQ treated patients in the short-term studies, up to 8 weeks, were: nausea (4%); dizziness, headache and vomiting (2% each). In a longer-term study, up to 9 months, the most common was vomiting (2%). **Common adverse reactions in placebo-controlled MDD studies—**The most commonly observed adverse reactions in PRISTIQ treated MDD patients in pre-marketing pooled 8-week, placebo-controlled fixed-dose studies (incidence ≥5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders. The incidence of common adverse reactions that occurred in ≥2% of PRISTIQ treated MDD patients and twice the rate of placebo at any dose in the pre-marketing pooled 8-week, placebo-controlled, fixed dose clinical studies (placebo, n=636; PRISTIQ 50 mg, n=317; PRISTIQ 100 mg, n=424; PRISTIQ 200 mg, n=307; PRISTIQ 400 mg, n=317) included: **Cardiac disorders:** Blood pressure increased (1% placebo, 1% PRISTIQ 50 mg, 1% PRISTIQ 100 mg, 2% PRISTIQ 200 mg, 2% PRISTIQ 400 mg); **Gastrointestinal disorders:** Nausea (10% placebo, 22% PRISTIQ 50 mg, 26% PRISTIQ 100 mg, 36% PRISTIQ 200 mg, 41% PRISTIQ 400 mg), Dry mouth (9% placebo, 11% PRISTIQ 50 mg, 17% PRISTIQ 100 mg, 21% PRISTIQ 200 mg, 25% PRISTIQ 400 mg), Constipation (4% placebo, 9% PRISTIQ 50 mg, 9% PRISTIQ 100 mg, 10% PRISTIQ 200 mg, 14% PRISTIQ 400 mg), Vomiting (3% placebo, 3% PRISTIQ 50 mg, 4% PRISTIQ 100 mg, 6% PRISTIQ 200 mg, 9% PRISTIQ 400 mg); **General disorders and administration site conditions:** Fatigue (4% placebo, 7% PRISTIQ 50 mg, 7% PRISTIQ 100 mg, 10% PRISTIQ 200 mg, 11% PRISTIQ 400 mg), Chills (1% placebo, 1% PRISTIQ 50 mg, <1% PRISTIQ 100 mg, 3% PRISTIQ 200 mg, 4% PRISTIQ 400 mg), Feeling jittery (1% placebo, 1% PRISTIQ 50 mg, 2% PRISTIQ 100 mg, 3% PRISTIQ 200 mg, 3% PRISTIQ 400 mg); **Metabolism and nutrition disorders:** Decreased appetite (2% placebo, 5% PRISTIQ 50 mg, 8% PRISTIQ 100 mg, 10% PRISTIQ 200 mg, 10% PRISTIQ 400 mg); **Nervous system disorders:** Dizziness (6% placebo, 13% PRISTIQ 50 mg, 10% PRISTIQ 100 mg, 15% PRISTIQ 200 mg, 16% PRISTIQ 400 mg), Somnolence (4% placebo, 4% PRISTIQ 50

mg, 9% PRISTIQ 100 mg, 12% PRISTIQ 200 mg, 12% PRISTIQ 400 mg), Tremor (2% placebo, 2% PRISTIQ 50 mg, 3% PRISTIQ 100 mg, 9% PRISTIQ 200 mg, 9% PRISTIQ 400 mg), Disturbance in attention (<1% placebo, <1% PRISTIQ 50 mg, 1% PRISTIQ 100 mg, 2% PRISTIQ 200 mg, 1% PRISTIQ 400 mg). **Psychiatric disorders:** Insomnia (6% placebo, 3% PRISTIQ 50 mg, 12% PRISTIQ 100 mg, 14% PRISTIQ 200 mg, 15% PRISTIQ 400 mg), Anxiety (2% placebo, 3% PRISTIQ 50 mg, 5% PRISTIQ 100 mg, 4% PRISTIQ 200 mg, 4% PRISTIQ 400 mg), Nervousness (1% placebo, <1% PRISTIQ 50 mg, 1% PRISTIQ 100 mg, 2% PRISTIQ 200 mg, 2% PRISTIQ 400 mg), Abnormal dreams (1% placebo, 2% PRISTIQ 50 mg, 3% PRISTIQ 100 mg, 2% PRISTIQ 200 mg, 4% PRISTIQ 400 mg); **Renal and urinary disorders:** Urinary hesitation (0% placebo, <1% PRISTIQ 50 mg, 1% PRISTIQ 100 mg, 2% PRISTIQ 200 mg, 2% PRISTIQ 400 mg); **Respiratory, thoracic and mediastinal disorders:** Yawning (<1% placebo, 1% PRISTIQ 50 mg, 1% PRISTIQ 100 mg, 4% PRISTIQ 200 mg, 3% PRISTIQ 400 mg); **Skin and subcutaneous tissue disorders:** Hyperhidrosis (4% placebo, 10% PRISTIQ 50 mg, 11% PRISTIQ 100 mg, 18% PRISTIQ 200 mg, 21% PRISTIQ 400 mg); **Special Senses:** Vision blurred (1% placebo, 3% PRISTIQ 50 mg, 4% PRISTIQ 100 mg, 4% PRISTIQ 200 mg, 4% PRISTIQ 400 mg), Mydriasis (<1% placebo, 2% PRISTIQ 50 mg, 2% PRISTIQ 100 mg, 6% PRISTIQ 200 mg, 6% PRISTIQ 400 mg), Vertigo (1% placebo, 2% PRISTIQ 50 mg, 1% PRISTIQ 100 mg, 5% PRISTIQ 200 mg, 3% PRISTIQ 400 mg), Tinnitus (1% placebo, 2% PRISTIQ 50 mg, 1% PRISTIQ 100 mg, 1% PRISTIQ 200 mg, 2% PRISTIQ 400 mg), Dysgeusia (1% placebo, 1% PRISTIQ 50 mg, 1% PRISTIQ 100 mg, 1% PRISTIQ 200 mg, 2% PRISTIQ 400 mg); **Vascular disorders:** Hot flush (<1% placebo, 1% PRISTIQ 50 mg, 1% PRISTIQ 100 mg, 2% PRISTIQ 200 mg, 2% PRISTIQ 400 mg).

Sexual function adverse reactions—The incidence of sexual function adverse reactions that occurred in >2% of PRISTIQ treated MDD patients in any fixed-dose group (pre-marketing pooled 8-week, placebo-controlled, fixed-dose, clinical studies) included Men only (placebo, n=239; PRISTIQ 50 mg, n=108; PRISTIQ 100 mg, n=157; PRISTIQ 200 mg, n=131; PRISTIQ 400 mg, n=154): Anorgasmia (0% placebo, 0% PRISTIQ 50 mg, 3% PRISTIQ 100 mg, 5% PRISTIQ 200 mg, 8% PRISTIQ 400 mg), Libido decreased (1% placebo, 4% PRISTIQ 50 mg, 5% PRISTIQ 100 mg, 6% PRISTIQ 200 mg, 3% PRISTIQ 400 mg), Orgasm abnormal (0% placebo, 0% PRISTIQ 50 mg, 1% PRISTIQ 100 mg, 2% PRISTIQ 200 mg, 3% PRISTIQ 400 mg), Ejaculation delayed (<1% placebo, 1% PRISTIQ 50 mg, 5% PRISTIQ 100 mg, 7% PRISTIQ 200 mg, 6% PRISTIQ 400 mg), Erectile dysfunction (1% placebo, 3% PRISTIQ 50 mg, 6% PRISTIQ 100 mg, 8% PRISTIQ 200 mg, 11% PRISTIQ 400 mg), Ejaculation disorder (0% placebo, 0% PRISTIQ 50 mg, 1% PRISTIQ 100 mg, 2% PRISTIQ 200 mg, 5% PRISTIQ 400 mg), Ejaculation failure (0% placebo, 1% PRISTIQ 50 mg, 0% PRISTIQ 100 mg, 2% PRISTIQ 200 mg, 2% PRISTIQ 400 mg), Sexual dysfunction (0% placebo, 1% PRISTIQ 50 mg, 0% PRISTIQ 100 mg, 0% PRISTIQ 200 mg, 2% PRISTIQ 400 mg); Women only (placebo, n=397; PRISTIQ 50 mg, n=209; PRISTIQ 100 mg, n=267; PRISTIQ 200 mg, n=176; PRISTIQ 400 mg, n=163): Anorgasmia (0% placebo, 1% PRISTIQ 50 mg, 1% PRISTIQ 100 mg, 0% PRISTIQ 200 mg, 3% PRISTIQ 400 mg).

Other adverse reactions observed in pre-marketing and post-marketing clinical studies: Other infrequent adverse reactions, not described elsewhere in the label, occurring at an incidence of <2% in MDD patients treated with PRISTIQ were: **Cardiac disorders**—Tachycardia; **General disorders and administration site conditions**—Asthenia; **Investigations**—Weight increased, liver function test abnormal, blood prolactin increased; **Musculoskeletal and connective tissue disorders**—Musculoskeletal stiffness; **Nervous system disorders**—Syncope, convulsion, dystonia; **Psychiatric disorders**—Depersonalization, bruxism; **Renal and urinary disorders**—Urinary retention; **Skin and subcutaneous tissue disorders**—Rash, alopecia, photosensitivity reaction, angioedema. In clinical studies, there were uncommon reports of ischemic cardiac adverse reactions, including myocardial ischemia, myocardial infarction, and coronary occlusion requiring revascularization; these patients had multiple underlying cardiac risk factors. More patients experienced these events during PRISTIQ treatment as compared to placebo.

Laboratory, ECG and vital sign changes observed in MDD clinical studies—The following changes were observed in pre-marketing placebo-controlled, short-term MDD studies with PRISTIQ. **Lipids**—Elevations in fasting serum total cholesterol, LDL (low density lipoproteins) cholesterol, and triglycerides occurred in the controlled studies. Some of these abnormalities were considered potentially clinically significant. The percentage of patients who exceeded a predetermined threshold value included: Total Cholesterol increase of ≥ 50 mg/dl and an absolute value of ≥ 261 mg/dl (2% placebo, 3% PRISTIQ 50 mg, 4% PRISTIQ 100 mg, 4% PRISTIQ 200 mg, 10% PRISTIQ 400 mg), LDL Cholesterol increase 50 mg/dl and an absolute value of 190 mg/dl (0% placebo, 1% PRISTIQ 50 mg, 0% PRISTIQ 100 mg, 1% PRISTIQ 200 mg, 2% PRISTIQ 400 mg), Triglycerides, fasting, ≥ 327 mg/dl (3% placebo, 2% PRISTIQ 50 mg, 1% PRISTIQ 100 mg, 4% PRISTIQ 200 mg, 6% PRISTIQ 400 mg).

Proteinuria—Proteinuria, greater than or equal to trace, was observed in the pre-marketing fixed-dose controlled studies. This proteinuria was not associated with increases in BUN or creatinine and was generally transient. The percentages of patients with proteinuria in the fixed-dose clinical studies were: 4% placebo, 6% PRISTIQ 50 mg, 8% PRISTIQ 100 mg, 5% PRISTIQ 200 mg, 7% PRISTIQ 400 mg.

Vital sign changes—Mean changes observed in placebo-controlled, short-term, fixed-dose, pre-marketing, controlled studies with PRISTIQ in patients with MDD included: **Blood pressure:** Supine systolic bp (-1.4 mm Hg placebo, 1.2 mm Hg PRISTIQ 50 mg, 2.0 mm Hg PRISTIQ 100 mg, 2.5 mm Hg PRISTIQ 200 mg, 2.1 mm Hg PRISTIQ 400 mg); Supine diastolic bp (-0.6 mm Hg placebo, 0.7 mm Hg PRISTIQ 50 mg, 0.8 mm Hg PRISTIQ 100 mg, 1.8 mm Hg PRISTIQ 200 mg, 2.3 mm Hg PRISTIQ 400 mg); **Pulse rate:** Supine pulse (-0.3 bpm placebo, 1.3 bpm PRISTIQ 50 mg, 1.3 bpm PRISTIQ 100 mg, 0.9 bpm PRISTIQ 200 mg, 4.1 bpm PRISTIQ 400 mg); **Weight:** (0.0 kg placebo, -0.4 kg PRISTIQ 50 mg, -0.6 kg PRISTIQ 100 mg, -0.9 kg PRISTIQ 200 mg, -1.1 kg PRISTIQ 400 mg).

Treatment with PRISTIQ at all doses from 50 mg/day to 400 mg/day in controlled studies was associated with sustained hypertension, defined as treatment-emergent supine diastolic blood pressure (SDBP) ≥ 90 mm Hg and ≥ 10 mm Hg above baseline for 3 consecutive on-therapy visits. The proportion of patients with sustained elevation of supine diastolic blood pressure included 0.5% placebo, 1.3% PRISTIQ 50 mg, 0.7% PRISTIQ 100 mg, 1.1% PRISTIQ 200 mg, 2.3% PRISTIQ 400 mg. Analyses of patients in PRISTIQ pre-marketing short-term controlled studies who met criteria for sustained hypertension revealed a consistent increase in the proportion of patients who developed sustained hypertension. This was seen at all doses with a suggestion of a higher rate at 400 mg/day.

Orthostatic hypotension—In the pre-marketing short-term, placebo-controlled clinical studies with doses of 50 to 400 mg, systolic orthostatic hypotension (decrease ≥ 30 mm Hg from supine to standing position) occurred more frequently in patients ≥ 65 years of age receiving PRISTIQ (8%, 7/87) versus placebo (2.5%, 1/40), compared to patients <65 years of age receiving PRISTIQ (0.9%, 18/1,937) versus placebo (0.7%, 8/1,218).

Post-marketing Experience—The following adverse reaction has been identified during post-approval use of PRISTIQ. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. **Skin and subcutaneous tissue disorders**—Stevens-Johnson syndrome. **DRUG INTERACTIONS: Monoamine Oxidase Inhibitors (MAOI)**—[see Dosage and Administration (2.6), Contraindications (4) and Warnings and Precautions (5.2) in the full prescribing information].

Serotonergic Drugs—[see Dosage and Administration (2.6), Contraindications (4) and Warnings and Precautions (5.2) in the full prescribing information]. **Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin)**—Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding. These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding. Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs and SNRIs are co-administered with warfarin. Patients receiving warfarin therapy should be carefully monitored when PRISTIQ is initiated or discontinued [see Warnings and Precautions (5.4) in the full prescribing information].

Potential for Other Drugs to Affect Desvenlafaxine—Based on *in vitro* data, no dose adjustment is required for PRISTIQ when used concomitantly with inhibitors of CYP3A4 and CYP1A1, 1A2, 2A6, 2D6, 2C8, 2C9, 2C19, 2E1, and the P-glycoprotein transporter. Clinical studies have demonstrated no clinically significant pharmacokinetic interaction between PRISTIQ and strong CYP3A4 inhibitors [see Figure 1 in full prescribing information].

Potential for Desvenlafaxine to Affect Other Drugs—Clinical studies have shown that desvenlafaxine does not have a clinically relevant effect on CYP2D6 metabolism at the dose of 100 mg daily [see Figure 2 in full prescribing information]. Substrates primarily metabolized by CYP2D6 (e.g., desipramine, atomoxetine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine) should be dosed at the original level when co-administered with PRISTIQ 100 mg or lower or when PRISTIQ is discontinued. Reduce the dose of these substrates by one-half if co-administered with 400 mg of PRISTIQ. No additional dose adjustment is required for concomitant use of substrates of CYP3A4, 1A2, 2A6, 2C8, 2C9, and 2C19 isozymes, and P-glycoprotein transporter. Clinical studies have demonstrated no clinically significant pharmacokinetic interaction between PRISTIQ and CYP3A4 substrates [see Figure 2 in full prescribing information]. Clinical studies have shown that desvenlafaxine (100 mg daily) does not have a clinically relevant effect on tamoxifen and apripazole, compounds that are metabolized by a combination of both CYP2D6 and CYP3A4 enzymes [see Figure 2 in full prescribing information]. *In vitro* studies showed minimal

inhibition effect of desvenlafaxine on the CYP2D6 isoenzyme. *In vitro*, desvenlafaxine does not inhibit or induce the CYP3A4 isozyme. *In vitro*, desvenlafaxine does not inhibit CYP1A2, 2A6, 2C8, 2C9, and 2C19 isozymes, and P-glycoprotein transporter and would not be expected to affect the pharmacokinetics of drugs that are substrates of these CYP isozymes and transporter. **Other Drugs Containing Desvenlafaxine or Venlafaxine**—Avoid use of PRISTIQ with other desvenlafaxine-containing products or venlafaxine products. The concomitant use of PRISTIQ with other desvenlafaxine-containing products or venlafaxine will increase desvenlafaxine blood levels and increase dose-related adverse reactions [see Adverse Reactions (6) in the full prescribing information]. **Ethanol**—A clinical study has shown that PRISTIQ does not increase the impairment of mental and motor skills caused by ethanol. However, as with all CNS-active drugs, patients should be advised to avoid alcohol consumption while taking PRISTIQ. **Drug-Laboratory Test Interactions**—False-positive urine immunoassay screening test for phenylclidine (PCP) and amphetamine have been reported in patients taking desvenlafaxine. This is due to lack of specificity of the screening tests. False positive test results may be expected for several days following discontinuation of desvenlafaxine therapy. Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish desvenlafaxine from PCP and amphetamine.

USE IN SPECIFIC POPULATIONS: Pregnancy—Pregnancy Category C: Risk summary—There are no adequate and well-controlled studies of PRISTIQ in pregnant women. In reproductive developmental studies in rats and rabbits with desvenlafaxine succinate, evidence of teratogenicity was not observed at doses up to 30 times a human dose of 100 mg/day (on a mg/m² basis) in rats, and up to 15 times a human dose of 100 mg/day (on a mg/m² basis) in rabbits. An increase in rat pup deaths was seen during the first 4 days of lactation when dosing occurred during gestation and lactation, at doses greater than 10 times a human dose of 100 mg/day (on a mg/m² basis). PRISTIQ should be used during pregnancy only if the potential benefits justify the potential risks to the fetus. **Clinical considerations**—A prospective longitudinal study of 201 women with history of major depression who were euthymic at the beginning of pregnancy, showed women who discontinued antidepressant medication during pregnancy were more likely to experience a relapse of major depression than women who continued antidepressant medication. **Human data**—Neonates exposed to SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors), or SSRIs (Selective Serotonin Reuptake Inhibitors), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome [see Warnings and Precautions (5.2) in the full prescribing information].

Animal data—When desvenlafaxine succinate was administered orally to pregnant rats and rabbits during the period of organogenesis at doses up to 300 mg/kg/day and 75 mg/kg/day, respectively, no teratogenic effects were observed. These doses are 30 times a human dose of 100 mg/day (on a mg/m² basis) in rats and 15 times a human dose of 100 mg/day (on a mg/m² basis) in rabbits. However, fetal weights were decreased and skeletal ossification was delayed in rats in association with maternal toxicity at the highest dose, with a no-effect dose 10 times a human dose of 100 mg/day (on a mg/m² basis). When desvenlafaxine succinate was administered orally to pregnant rats throughout gestation and lactation, there was a decrease in pup weights and an increase in pup deaths during the first four days of lactation at the highest dose of 300 mg/kg/day. The cause of these deaths is not known. The no-effect dose for rat pup mortality was 10 times a human dose of 100 mg/day (on a mg/m² basis). Post-weaning growth and reproductive performance of the progeny were not affected by maternal treatment with desvenlafaxine succinate at a dose 30 times a human dose of 100 mg/day (on a mg/m² basis). **Nursing Mothers**—Desvenlafaxine (O-desmethylvenlafaxine) is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from PRISTIQ, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. **Pediatric Use**—Safety and effectiveness in pediatric patients have not been established [see Boxed Warning and Warnings and Precautions (5.1) in the full prescribing information]. Anyone considering the use of PRISTIQ in a child or adolescent must balance the potential risks with the clinical need. **Geriatric Use**—Of the 4,158 patients in pre-marketing clinical studies with PRISTIQ, 6% were 65 years of age or older. No overall differences in safety or efficacy were observed between these patients and younger patients; however, in the short-term placebo-controlled studies, there was a higher incidence of systolic orthostatic hypotension in patients ≥ 65 years of age compared to patients <65 years of age treated with PRISTIQ [see Adverse Reactions (6) in the full prescribing information]. For elderly patients, possible reduced renal clearance of PRISTIQ should be considered when determining dose [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3) in the full prescribing information]. SSRIs and SNRIs, including PRISTIQ, have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse event [see Warnings and Precautions (5.9) in the full prescribing information].

Other Patient Factors: The effect of intrinsic patient factors on the pharmacokinetics of PRISTIQ is presented in Figure 3 (refer to figure in full prescribing information). **Renal Impairment**—In subjects with renal impairment the clearance of PRISTIQ was decreased. In subjects with severe renal impairment (24-hr CrCl <30 mL/min, Cockcroft-Gault) and end-stage renal disease, elimination half-lives were significantly prolonged, increasing exposures to PRISTIQ; therefore, dosage adjustment is recommended in these patients [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3) in the full prescribing information]. **Hepatic Impairment**—The mean terminal half-life (t_{1/2}) changed from approximately 10 hours in healthy subjects and subjects with mild hepatic impairment to 13 and 14 hours in moderate and severe hepatic impairment, respectively. The recommended dose in patients with moderate to severe hepatic impairment is 50 mg/day. Dose escalation above 100 mg/day is not recommended [see Clinical Pharmacology (12.3) in the full prescribing information].

DRUG ABUSE AND DEPENDENCE: Controlled Substance—PRISTIQ is not a controlled substance. **OVERDOSAGE: Human Experience with Overdosage**—There is limited clinical trial experience with desvenlafaxine succinate overdosage in humans. However, desvenlafaxine (PRISTIQ) is the major active metabolite of venlafaxine. Overdose experience reported with venlafaxine (the parent drug of PRISTIQ) is presented below; the identical information can be found in the Overdosage section of the venlafaxine package insert. In post-marketing experience, overdose with venlafaxine (the parent drug of PRISTIQ) has occurred predominantly in combination with alcohol and/or other drugs. The most commonly reported events in overdose include tachycardia, changes in level of consciousness (ranging from somnolence to coma), mydriasis, seizures, and vomiting. Electrocardiogram changes (e.g., prolongation of QT interval, bundle branch block, QRS prolongation), sinus and ventricular tachycardia, bradycardia, hypotension, rhabdomyolysis, vertigo, liver necrosis, serotonin syndrome, and death have been reported. Published retrospective studies report that venlafaxine overdosage may be associated with an increased risk of fatal outcomes compared to that observed with SSRI antidepressant products, but lower than that for tricyclic antidepressants. Epidemiological studies have shown that venlafaxine-treated patients have a higher pre-existing burden of suicide risk factors than SSRI-treated patients. The extent to which the finding of an increased risk of fatal outcomes can be attributed to the toxicity of venlafaxine in overdose, as opposed to some characteristic(s) of venlafaxine-treated patients, is not clear. **Management of Overdosage**—No specific antidotes for PRISTIQ are known. In managing overdose, consider the possibility of multiple drug involvement. In case of overdose, call Poison Control Center at 1-800-222-1222 for latest recommendations.

Rx only
This brief summary is based on PRISTIQ Prescribing Information LAB-0452-14.0, revised March 2015.

POF758607-03 © 2015 Pfizer Inc. All rights reserved July 2015



MDD can make even small things feel overwhelming

Prescribe PRISTIQ® (desvenlafaxine) for your adult patients with major depressive disorder (MDD)

PRISTIQ has proven efficacy with a low discontinuation rate due to adverse events and a reduced risk of relapse in PRISTIQ responders^{1,2*}

- In patients taking PRISTIQ 50 mg, the most commonly observed adverse reactions vs placebo include nausea (22% vs 10%), dizziness (13% vs 5%), hyperhidrosis (10% vs 4%), constipation (9% vs 4%), and decreased appetite (5% vs 2%)

*In a pooled analysis of 8-week studies, discontinuation rates were 4.1% with PRISTIQ 50 mg vs 3.8% with placebo. In a study of adult MDD patients who responded to 8 weeks of open-label acute treatment with PRISTIQ 50 mg and remained stable on PRISTIQ 50 mg for 12 additional weeks, the probability of relapse was reduced by more than half vs placebo (14% vs 30%) during the 6-month double-blind phase. For most patients, 50 mg per day is the recommended dose. The maximum recommended dose in patients with severe renal impairment (24-hr CrCl less than 30 mL/min, C-G) or end-stage renal disease (ESRD) is 25 mg every day or 50 mg every other day. Supplemental doses should not be given to patients after dialysis.

Indication

PRISTIQ Extended-Release Tablets are indicated for the treatment of major depressive disorder in adults.

Important Safety Information for PRISTIQ

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older.

In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. PRISTIQ is not approved for use in pediatric patients.

Contraindications

- PRISTIQ is contraindicated in patients with a known hypersensitivity to PRISTIQ or venlafaxine. Angioedema has been reported in patients treated with PRISTIQ.
- **Serotonin syndrome and MAOIs:** Do not use MAOIs intended to treat psychiatric disorders with PRISTIQ or within 7 days of stopping treatment with PRISTIQ. Do not use PRISTIQ within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start PRISTIQ in a patient who is being treated with an MAOI such as linezolid or intravenous methylene blue.

Selected Warnings and Precautions

- All patients treated with antidepressants should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of treatment and when changing the dose. Consider changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse or includes symptoms of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania, or suicidality that are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Families and caregivers of patients being treated with antidepressants should be alerted about the need to monitor patients.
- The development of a potentially life-threatening serotonin syndrome has been reported with SSRIs and SNRIs, including with PRISTIQ, both when taken alone, but especially when co-administered with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue). If such events occur, immediately discontinue PRISTIQ and any concomitant serotonergic agents, and initiate supportive treatment. If concomitant use of PRISTIQ with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increase.

Help your patients save on their prescriptions



The cost of PRISTIQ may be comparable to many generic antidepressants for your eligible patients with the PRISTIQ \$4 Co-pay Card.^{†‡§}

To order Co-pay Cards or for more information, visit PRISTIQHCP.com/Co-pay

- Patients receiving PRISTIQ should have regular monitoring of blood pressure, since increases in blood pressure were observed in clinical studies. Pre-existing hypertension should be controlled before starting PRISTIQ. Caution should be exercised in treating patients with pre-existing hypertension, cardiovascular or cerebrovascular conditions that might be compromised by increases in blood pressure. Cases of elevated blood pressure requiring immediate treatment have been reported. For patients who experience a sustained increase in blood pressure, either dose reduction or discontinuation should be considered.
- SSRIs and SNRIs, including PRISTIQ, may increase the risk of bleeding events. Concomitant use of aspirin, NSAIDs, warfarin, and other anticoagulants may add to this risk.
- The pupillary dilation that occurs following use of many antidepressant drugs including PRISTIQ may trigger an angle closure attack in a patient with anatomically narrow angles (Angle Closure Glaucoma) who does not have a patent iridectomy.
- PRISTIQ is not approved for use in bipolar depression. Prior to initiating treatment with an antidepressant, patients should be adequately screened to determine the risk of bipolar disorder.
- PRISTIQ should be used cautiously in patients with a history or family history of mania or hypomania or with a history of seizure disorder.
- On discontinuation, adverse events, some of which may be serious, have been reported with PRISTIQ and other SSRIs and SNRIs. Abrupt discontinuation of PRISTIQ has been associated with the appearance of new symptoms. Patients should be monitored for symptoms when discontinuing treatment. A gradual reduction in dose rather than abrupt cessation is recommended whenever possible.
- Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including PRISTIQ. Discontinuation of PRISTIQ should be considered in patients with symptomatic hyponatremia.
- Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine (the parent drug of PRISTIQ) therapy have been rarely reported.

Adverse Reactions

- The most commonly observed adverse reactions in patients taking PRISTIQ vs placebo for MDD in short-term fixed-dose premarketing studies (incidence $\geq 5\%$ and at least twice the rate of placebo in the 50-mg dose group) were nausea (22% vs 10%), dizziness (13% vs 5%), hyperhidrosis (10% vs 4%), constipation (9% vs 4%), and decreased appetite (5% vs 2%).

References: 1. Thase ME, Kornstein SG, Germain JM, Jiang Q, Guico-Pabia C, Ninan PT. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. *CNS Spectr*. 2009;14(3):144-154. 2. Rosenthal JZ, Boyer P, Viallet C, Hwang E, Tourian KA. Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder: a randomized controlled trial. *J Clin Psychiatry*. 2013;74(2):158-166.

Please see brief summary of full Prescribing Information on adjacent pages.

[†]According to IMS Pharmacy Benchmarks, created from National Prescription Audit[™] (NPA), the average co-pay of generic antidepressants, based on Moving Annual Total (MAT) as of April 2016, may range between \$3.31 and \$105.34 (for branded generic selegiline).

[‡]Does not imply comparable efficacy or safety. Products may have different indications.

[§]Eligibility required. Terms and conditions apply. Card will be accepted only at participating pharmacies. Card is not health insurance. No membership fees. The maximum savings per month is \$75 and the maximum savings per calendar year is \$900. For more information, visit www.PRISTIQ.com/terms, call 1-855-440-6852, or write: PRISTIQ \$4 Co-pay Card, 2250 Perimeter Park Drive, Suite 300, Morrisville, NC 27560.